Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer
Counterpart Health, a subsidiary of Clover Health (Nasdaq: CLOV), has appointed David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will advance Counterpart's clinical strategy and product roadmap for Counterpart Assistant, an AI-powered physician enablement platform. With over two decades of experience in health technology and clinical innovation, Dr. Tsay previously held leadership roles at Cue Health, Apple, and New York-Presbyterian.
Counterpart Health's CEO, Conrad Wai, expressed confidence in Dr. Tsay's ability to accelerate the company's expansion into value-based healthcare networks. Dr. Tsay highlighted Counterpart Assistant as an innovative solution for providers looking to deliver value-based care. The platform aims to reduce the total cost of care in value-based models through advanced chronic disease management.
Counterpart Health, una consociata di Clover Health (Nasdaq: CLOV), ha nominato David Tsay M.D., Ph.D come Chief Medical Officer (CMO). Il Dr. Tsay avanzerà la strategia clinica di Counterpart e la roadmap del prodotto per Counterpart Assistant, una piattaforma di abilitazione per i medici basata sull'IA. Con oltre vent'anni di esperienza nella tecnologia sanitaria e innovazione clinica, il Dr. Tsay ha ricoperto ruoli di leadership in Cue Health, Apple e New York-Presbyterian.
Il CEO di Counterpart Health, Conrad Wai, ha espresso fiducia nella capacità del Dr. Tsay di accelerare l'espansione dell'azienda nelle reti sanitarie basate sul valore. Il Dr. Tsay ha evidenziato Counterpart Assistant come una soluzione innovativa per i fornitori che cercano di offrire assistenza basata sul valore. La piattaforma mira a ridurre il costo totale delle cure nei modelli basati sul valore attraverso una gestione avanzata delle malattie croniche.
Counterpart Health, una subsidiaria de Clover Health (Nasdaq: CLOV), ha nombrado al Dr. David Tsay M.D., Ph.D como Director Médico (CMO). El Dr. Tsay impulsará la estrategia clínica de Counterpart y la hoja de ruta del producto para Counterpart Assistant, una plataforma de habilitación para médicos impulsada por IA. Con más de dos décadas de experiencia en tecnología de salud e innovación clínica, el Dr. Tsay ocupó roles de liderazgo en Cue Health, Apple y New York-Presbyterian.
El CEO de Counterpart Health, Conrad Wai, expresó confianza en la capacidad del Dr. Tsay para acelerar la expansión de la empresa en redes de atención médica basadas en el valor. El Dr. Tsay destacó a Counterpart Assistant como una solución innovadora para los proveedores que buscan ofrecer atención basada en el valor. La plataforma tiene como objetivo reducir el costo total de la atención en modelos basados en el valor a través de una gestión avanzada de enfermedades crónicas.
카운터파트 헬스는 클로버 헬스 (Nasdaq: CLOV)의 자회사로 David Tsay M.D., Ph.D를 최고 의료 책임자 (CMO)로 임명했습니다. Tsay 박사는 Counterpart Assistant의 임상 전략 및 제품 로드맵을 발전시킬 것입니다. 20년 이상의 건강 기술 및 임상 혁신 경험을 보유하고 있는 Tsay 박사는 Cue Health, Apple, New York-Presbyterian에서 리더십 역할을 수행했습니다.
카운터파트 헬스의 CEO인 Conrad Wai는 Tsay 박사가 가치 기반 의료 네트워크로의 회사 확장을 가속화할 능력을 가지고 있다고 확신을 표명했습니다. Tsay 박사는 제공자가 가치 기반 치료를 제공하려는 혁신적인 솔루션으로 Counterpart Assistant를 강조했습니다. 이 플랫폼은 만성 질환 관리를 통해 가치 기반 모델에서 총 치료 비용을 줄이는 것을 목표로 합니다.
Counterpart Health, une filiale de Clover Health (Nasdaq: CLOV), a nommé David Tsay M.D., Ph.D au poste de Directeur Médical (CMO). Le Dr. Tsay fera avancer la stratégie clinique de Counterpart et la feuille de route pour Counterpart Assistant, une plateforme d'habilitation des médecins powered by IA. Fort de plus de 20 ans d'expérience en technologie de la santé et innovation clinique, le Dr. Tsay a précédemment occupé des postes de direction chez Cue Health, Apple et New York-Presbyterian.
Le PDG de Counterpart Health, Conrad Wai, a exprimé sa confiance dans la capacité du Dr. Tsay à accélérer l'expansion de l'entreprise dans les réseaux de soins de santé basés sur la valeur. Le Dr. Tsay a souligné Counterpart Assistant comme une solution innovante pour les prestataires cherchant à offrir des soins basés sur la valeur. La plateforme vise à réduire le coût total des soins dans les modèles basés sur la valeur grâce à une gestion avancée des maladies chroniques.
Counterpart Health, eine Tochtergesellschaft von Clover Health (Nasdaq: CLOV), hat David Tsay M.D., Ph.D zum Chief Medical Officer (CMO) ernannt. Dr. Tsay wird die klinische Strategie von Counterpart und die Produkt-Roadmap für Counterpart Assistant, eine KI-gestützte Plattform zur Unterstützung von Ärzten, vorantreiben. Mit über zwei Jahrzehnten Erfahrung in der Gesundheitstechnologie und klinischen Innovationen hatte Dr. Tsay zuvor Führungspositionen bei Cue Health, Apple und New York-Presbyterian inne.
Der CEO von Counterpart Health, Conrad Wai, äußerte Vertrauen in die Fähigkeit von Dr. Tsay, die Expansion des Unternehmens in wertbasierte Gesundheitsnetze zu beschleunigen. Dr. Tsay hob Counterpart Assistant als innovative Lösung für Anbieter hervor, die wertbasierte Pflege anbieten möchten. Die Plattform zielt darauf ab, die Gesamtkosten der Pflege in wertbasierten Modellen durch ein fortschrittliches Management chronischer Krankheiten zu senken.
- Appointment of David Tsay M.D., Ph.D as Chief Medical Officer, bringing expertise in AI, digital health, and clinical innovation
- Potential for accelerated expansion into value-based healthcare networks and systems nationwide
- Counterpart Assistant platform designed to help reduce total cost of care in value-based care models
- None.
Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart’s clinical strategy and product roadmap for Counterpart Assistant, the company’s proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”).
David Tsay is a distinguished physician executive with deep expertise and over two decades of experience in health technology, product development, and clinical innovation. Prior to Counterpart, Dr. Tsay served in clinical leadership roles in the technology industry, most recently as Chief Medical Officer at Cue Health where he led regulatory, clinical, and medical affairs. Before Cue Health, Dr. Tsay led the clinical team for digital health medical device products at Apple. Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian (NYP), one of the nation's most comprehensive academic healthcare delivery systems, leading digital transformation initiatives for NYP in artificial intelligence, automation, and digital web/mobile technologies.
Dr. Tsay received his BA in Computer Science and Physics from Columbia University College, M.D., Ph.D degrees from Columbia University College of Physicians and Surgeons, and is board certified in internal medicine and cardiology.
"Counterpart Health is built on groundbreaking technology that empowers physicians to excel in value-based care, particularly in the management of chronic diseases," said Conrad Wai, CEO of Counterpart Health. "Dr. Tsay’s world-class expertise in clinical innovation and health technology makes him a valuable addition to our team. I’m confident that his leadership will be instrumental as we accelerate our expansion into more value-based healthcare networks and systems nationwide."
"I’ve had the privilege of contributing to world-class institutions like Apple and NewYork-Presbyterian, which operate at the critical crossroads of healthcare and technology. Counterpart attracted me because it offers one of the most compelling solutions I’ve encountered," Tsay remarked. "With an increasing number of providers looking to deliver value-based care, Counterpart Assistant provides an innovative technology designed specifically for this purpose. I look forward to working alongside this skilled team in its mission to help improve providers’ and patients’ lives."
For companies interested in learning more about how Counterpart can reduce the total cost of care in value-based care models through advanced chronic disease management, visit www.counterparthealth.com.
About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform. Counterpart Health’s flagship software platform, Counterpart Assistant, was incubated by Clover Health as Clover Assistant and has helped improve plan performance and clinical outcomes for Medicare members through proprietary AI technology. Counterpart Health extends the benefits of the data-driven technology platform outside of Clover Health’s Medicare Advantage plan to a wider audience, to enable enhanced patient outcomes and reduced healthcare costs nationwide. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.
Press Contact:
Andrew Still-Baxter
press@cloverhealth.com
Investor Relations Contact:
Ryan Schmidt
investors@cloverhealth.com
FAQ
Who is the new Chief Medical Officer of Counterpart Health?
What is Counterpart Health's relationship to Clover Health (CLOV)?
What is Counterpart Assistant?
How does Counterpart Health aim to impact value-based care?
